Model Predicts CRC Risk in Ulcerative Colitis Patients With LGD
FRIDAY, March 25, 2022 -- For patients with ulcerative colitis (UC), large, unresected, multifocal low-grade dysplasia (LGD) and recent moderate/severe histological inflammation are associated with elevated risk of developing advanced neoplasia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Upadacitinib for Ulcerative Colitis FDA Approves Upadacitinib for Ulcerative Colitis
Upadacitinib has been shown to rapidly control symptoms in adults with moderate to severe active ulcerative colitis. It ’s the first FDA approval for the JAK inhibitor in gastroenterology.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 17, 2022 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
Weighing the Best Diet Options for IBD
Nearly every patient with inflammatory bowel disease (IBD) has the same query—which has a not-so-simple answer.
“‘Doctor, what should I eat when living with IBD?’ is likely the most frequently asked question following diagnosis,” says Dr. Maitreyi Raman, an associate professor of medicine at the University of Calgary.
Raman, who’s a gastroenterologist, physician nutrition specialist, and researcher, has closely studied the topic and reviewed the available evidence for dietary patterns that may be of benefit (or not) to patients.
IBD includes Crohn’s disease, which can cause inflamm...
Source: TIME: Health - March 16, 2022 Category: Consumer Health News Authors: Michael O. Schroeder Tags: Uncategorized healthscienceclimate Source Type: news
Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., March 16, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults with moderately to severely active... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 16, 2022 Category: Drugs & Pharmacology Source Type: news
The Truth About Common Digestive Health Fears
Everyone experiences digestive problems now and then, and they’re nobody’s idea of a good time. In a survey of nearly 72,000 adults in the U.S., 61% reported having had at least one gastrointestinal (GI) symptom over the previous week, and within that group, 58% said they’d had two or more GI symptoms over the past week, according to a study in a 2018 issue of the American Journal of Gastroenterology. Because symptoms like constipation, heartburn, and abdominal pain are generally vague and often don’t have an obvious cause, those suffering tend to fear the worst.
“People get very concerned abo...
Source: TIME: Health - March 14, 2022 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized healthscienceclimate Source Type: news
Higher Adalimumab Dosing Regimens May Have Benefit in Ulcerative Colitis Higher Adalimumab Dosing Regimens May Have Benefit in Ulcerative Colitis
A higher-than-standard maintenance (but not induction) dosing regimen of adalimumab may be beneficial for some patients with moderate to severe ulcerative colitis, according to results of the SERENE UC study.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 11, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Safety and Efficacy of Tofacitinib for Ulcerative Colitis Safety and Efficacy of Tofacitinib for Ulcerative Colitis
This paper presents final data from OCTAVE Open, an open-label, long-term extension study on the safety and efficacy of the Janus kinase inhibitor tofacitinib for the treatment of ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 8, 2022 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news
Jab gives new hope to 146,000 Britons with ulcerative colitis
President John F Kennedy, pictured, suffered from ulcerative colitis which is caused when the immune system attacks the lining of the bowel or colon and affects 146,000 people in Britain. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2022 Category: Consumer Health News Source Type: news
AI Aids in Assessment of Ulcerative Colitis Activity, Remission AI Aids in Assessment of Ulcerative Colitis Activity, Remission
Artificial intelligence systems have the potential to supplement the services of expert histopathologists and endoscopists rather than replace them.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 4, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Inflammatory bowel disease in kids raises lifetime cancer risk, study finds
Children diagnosed with inflammatory bowel diseases, such as Crohn's and ulcerative colitis, are more than twice as likely to develop cancers later in life compared with others, a JAMA Network Open analysis found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 1, 2022 Category: Consumer Health News Source Type: news
What Causes Rectal Prolapse?
Discussion
Rectal prolapse is defined as a herniation of the rectum through the anal verge. In children it is also usually mucosal prolapse and not full thickness. Partial or mucosal prolapse usually is seen as radial folds occurring 1 – 2.5 cm from the anal verge. Full thickness will protrude more than 5 cm. It affects genders equally and occurs most commonly in children under age 4. This is due to vertical course and low position of the anus, looser supporting tissues and less muscular support. These children are more likely to have prolapse but are less likely to have it recur. After age 4 the rectum takes the adu...
Source: PediatricEducation.org - February 28, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Two Studies Shed Light on IBD Treatment After Anti-TNF Failure Two Studies Shed Light on IBD Treatment After Anti-TNF Failure
Separate studies compared vedolizumab with tofacitinib in ulcerative colitis and to ustekinumab in Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 24, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Post-marketing Safety Surveillance of Tofacitinib in UC Post-marketing Safety Surveillance of Tofacitinib in UC
This study evaluated the safety profile of tofacitinib in patients with ulcerative colitis in the post-marketing setting. Were adverse events consistent with those reported in clinical trials?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn's Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn's
Researchers evaluated results of seven major studies to compare efficacy and safety of the two agents in Crohn ' s disease and ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 23, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
CRP Can Help Assess Severity of Acute Ulcerative Colitis
THURSDAY, Feb. 17, 2022 -- A C-reactive protein (CRP) cutoff is a sensitive and practical alternative to erythrocyte sedimentation rate (ESR) as a criterion to help determine ulcerative colitis (UC) activity, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2022 Category: Pharmaceuticals Source Type: news
